GLP-1 and Depression: Evidence, FDA Review, and What to Watch
The question you’re asking
You know GLP-1 medications help with weight loss, but you’re wondering: what happens to your mood when you start? You may have read headlines about FDA warnings. Or maybe you struggle with depression and you’re trying to figure out whether GLP-1 is safe for you.
The answer is nuanced. The evidence suggests that GLP-1 medications may improve mood for some people, but they are not treatments for depression. The mechanisms are more complex than that. And yes, the FDA reviewed reports of suicidal thoughts and actions. Its reviews did not find that GLP-1 medications cause them, and in January 2026 it asked manufacturers to remove the suicidality warning from the labels that carried one. Here is what you need to know to make an informed decision with your provider.
How GLP-1 medications interact with the brain
GLP-1 (glucagon-like peptide-1) is not just a weight loss hormone. It is a signaling molecule that works throughout the body, including in the brain. GLP-1 receptors are found in several brain regions that regulate reward, mood, and emotional control, including the ventral tegmental area (involved in pleasure and motivation), the prefrontal cortex (involved in decision-making and emotional regulation), and the hippocampus (involved in memory and mood).
This is the biological foundation for the question: if GLP-1 acts on the brain, does it affect mood?
The short answer is, probably, but the effect is indirect and entangled with weight loss. That matters for how you interpret the clinical data.
What the clinical trials show
The SELECT trial and mood outcomes
The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 adults with overweight or obesity and existing cardiovascular disease, without diabetes, and followed them for an average of about 40 months.[1] It was designed to measure heart attacks, strokes, and cardiovascular deaths. Depression and anxiety scores were not among the outcomes reported in its main publication, so SELECT does not answer the mood question directly.
The clearest randomized data on mood come from the STEP weight-management trials of semaglutide 2.4 mg. A post hoc analysis of STEP 1, 2, 3, and 5, published in 2024, looked at depression symptoms (measured with the PHQ-9 questionnaire) and suicidal thoughts or behavior (measured with the Columbia-Suicide Severity Rating Scale).[2] Participants started with no or minimal depression symptoms. After 68 weeks, the semaglutide group had slightly lower depression scores than the placebo group, a statistically significant difference that the authors did not consider clinically meaningful. People on semaglutide were less likely to move into a more severe depression category. Suicidal thoughts or behavior were reported by 1% or fewer of participants, with no difference between semaglutide and placebo.[2]
Important context: These participants were not enrolled because they had depression, and people with known major psychiatric conditions were not part of the analysis. It was a post hoc analysis, done after the trials ended. And participants on semaglutide were losing more weight than those on placebo, which can itself affect mood. Results vary, and trial results describe study participants, not a prediction for any individual.
Separating medication-specific effects from weight loss effects is methodologically difficult. Any mood change may come from the direct neural action of semaglutide, from weight loss itself, or from both.
Real-world observational data
A 2024 study published in Nature Medicine used electronic health records from 240,618 people with overweight or obesity to compare semaglutide with weight loss medicines that are not GLP-1 medications.[3] Over 6 months, semaglutide was associated with a lower risk of new suicidal ideation and of recurrent suicidal ideation. Similar findings were seen in a separate group of people with type 2 diabetes. The authors concluded that their findings did not support a higher risk of suicidal ideation with semaglutide.[3]
Again, critical context: This was observational data, not a randomized controlled trial. People choosing to use GLP-1 medications differ from other groups in ways that matter. Socioeconomic status, health literacy, access to care, and baseline depression risk all influence who gets prescribed what. The researchers matched groups on measured characteristics, but unmeasured differences can remain. The observed result could reflect weight loss, GLP-1’s direct brain effects, unobserved patient characteristics, or some combination of these.
The mechanisms behind mood improvement
If GLP-1 medications do improve mood, how?
Weight loss and body image
This is the largest and most direct mechanism. Obesity and depression are bidirectionally linked. People with obesity have higher rates of depression, and people with depression have higher rates of weight gain and obesity. Weight loss reduces depression and anxiety in most populations, independent of medication type.
When you lose weight on a GLP-1 medication, you gain several psychological benefits: improved energy and physical function, better sleep quality, increased confidence, reduced shame and stigma, improved self-image. These are not pharmacological effects. They are behavioral and psychological, but they are real and powerful.
For many patients, this is the primary source of mood improvement.
Reduced food obsession and mental burden
One of GLP-1’s effects is to quiet “food noise,” the constant mental urge to think about food, plan the next meal, or resist cravings. Many patients report that this reduction in food preoccupation frees up mental energy, reduces anxiety around eating, and improves mood. This is related to weight loss (because food noise typically decreases as you lose weight) but is distinct from it. The mental relief itself improves quality of life and mood.
Direct brain action
GLP-1 receptors in the brain may have mood-relevant effects, based mainly on animal research. One hypothesis researchers are exploring is that GLP-1 activity may reduce inflammation in the brain, which has been linked to depression. If that holds in humans at the doses used for weight management, it could have a mood effect independent of weight loss.
However, this is still early-stage research. It has not been formally tested in a randomized trial with depression as a primary outcome. The clinical significance of these findings remains unclear.
The FDA safety review: what you should know
When Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) were approved for weight management, their labels included a warning about suicidal behavior and ideation. According to the FDA, that warning was based on reports seen with a variety of older weight loss medicines, not on a finding specific to GLP-1 medications.[5] GLP-1 labels for type 2 diabetes never carried it.
After receiving reports of suicidal thoughts or actions in people taking GLP-1 medications, the FDA reviewed reports in the FDA Adverse Event Reporting System (FAERS), clinical trials, and observational studies. In a January 11, 2024 Drug Safety Communication, it said its preliminary evaluation had not found evidence that GLP-1 medications cause suicidal thoughts or actions. Because the number of events was small, it said it could not definitively rule out a small risk and kept evaluating.[4]
On January 13, 2026, after what it called a comprehensive review that found no increased risk of suicidal ideation or behavior, the FDA asked manufacturers to remove the warning from the Wegovy, Zepbound, and Saxenda labels.[5] The current Wegovy and Zepbound prescribing information list the Suicidal Behavior and Ideation warning as removed under Recent Major Changes.[6][7]
Here is what this means in plain language:
The FAERS reports often had limited information, so they did not show a clear relationship with the medications.[4] The FAERS database (now called the FDA Adverse Event Monitoring System, or AEMS) collects voluntary reports from patients, healthcare providers, and manufacturers. A report does not prove that a drug caused an event. It identifies signals that warrant further investigation.
In this case, several factors complicate any causal inference:
Confounding by indication: Patients with obesity, metabolic syndrome, and type 2 diabetes have higher baseline rates of depression and suicidality than the general population. When you compare patients taking GLP-1 medications to the general population, you are not comparing equivalent groups.
Reporting bias: Media coverage of potential suicidality risks increases reporting of suicidal ideation among patients taking the medication, even if the risk has not changed. This is called stimulated reporting and is a known feature of the FAERS database.
Temporal association is not causation: The fact that a patient took GLP-1 and later experienced suicidal ideation does not mean the medication caused the ideation.
The FDA’s reviews of clinical trials, including large outcome studies, and of observational studies did not find an association between GLP-1 medications and suicidal thoughts or actions.[4][5] The FDA still tells patients to report new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior to their health care professional, and to call or text 988 for support.[5]
Compounded semaglutide and tirzepatide are not FDA-approved and have no FDA-approved labeling, and these FDA reviews and label changes concern the FDA-approved medications. Compounded products are not the same as brand-name products such as Wegovy or Zepbound, and the FDA does not review them for safety, effectiveness, or quality.
Important: GLP-1 medications are not treatments for depression
To be clear: GLP-1 medications are not approved by the FDA for depression. They are not used in clinical practice to treat depression. Even if some patients experience mood improvement while taking GLP-1 for weight loss, that does not make GLP-1 a depression treatment.
If you have clinical depression that requires treatment, talk to your provider or a mental health professional about evidence-based treatments like antidepressant medications, therapy, or both. GLP-1 may be an additional tool that supports your overall health and mood, but it should not replace psychiatric treatment.
What you should tell your provider
Many telehealth weight loss programs ask about mental health during intake, but the depth of screening varies by program. Whichever provider you choose, here is what they need to know:
Current mental health status: Do you currently have depression, anxiety, bipolar disorder, or other mood disorders? Are you in treatment?
Psychiatric medication history: Are you taking any antidepressants, anti-anxiety medications, mood stabilizers, or other psychiatric medications?
Past suicidality: Have you ever experienced suicidal thoughts or attempted suicide? When? Are you at risk now?
Mental health treatment: Are you currently working with a therapist, counselor, psychiatrist, or other mental health provider?
A licensed provider uses this information to decide whether GLP-1 treatment is medically appropriate for you. Having a history of depression does not automatically rule it out. But your provider needs to assess your current mental health status, your stability on any psychiatric medications, and your capacity to manage the behavioral demands of a GLP-1 program (dietary changes, medical appointments, self-monitoring).
What the research shows about mental health risk
You may have encountered conflicting headlines about GLP-1 medications and mental health. The data actually paints a more nuanced picture than the coverage suggests.
The STEP trial analysis covered people without known major psychiatric conditions and found no increase in depression symptoms or suicidal thoughts with semaglutide.[2] The 2024 Nature Medicine study of real-world records found a lower risk of suicidal ideation with semaglutide than with other weight loss medicines.[3]
A 2026 Swedish national cohort study published in The Lancet Psychiatry looked at a different group: people already diagnosed with depression, anxiety, or both. It used national health registers to follow 95,490 adults with those diagnoses who used any diabetes medication between 2009 and 2022, comparing periods when each person was taking a medication with periods when the same person was not. Compared with periods of not using GLP-1 medications, semaglutide use was associated with a 42% lower risk of worsening mental illness (a combined measure that included psychiatric hospitalization, long psychiatric sick leave, hospitalization for self-harm, or death by suicide). Semaglutide was also associated with a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety. Liraglutide showed a smaller association, and exenatide and dulaglutide showed none.[8]
Why does this matter? The STEP analysis left out people with known major psychiatric conditions. The Swedish cohort focused on people with diagnosed depression or anxiety, all of whom had used a diabetes medication. Its results suggest that semaglutide may not worsen, and may even help, mental health in this group. But it is an observational study, and the authors called for randomized trials to test these findings. It does not prove that GLP-1 medications protect against depression.
The practical implication for you: If you have a history of depression, anxiety, or another psychiatric condition, this is a conversation to have with your provider before starting GLP-1 treatment. These conditions are not necessarily a contraindication to treatment, but they warrant closer monitoring and clear communication about any mood changes during treatment. Your provider needs to know your baseline mental health status so they can assess whether treatment is appropriate and monitor you appropriately over time.
What mood changes to expect and monitor
Different people experience different mood effects on GLP-1. This is normal and individual.
Positive mood changes (reported by many people):
- Improved mood and sense of well-being as weight loss progresses
- Increased energy and motivation
- Reduced anxiety related to food and eating
- Improved confidence and self-image
- Better sleep quality
Early transient mood effects (usually temporary):
- Temporary irritability or low mood in the first 1-2 weeks, often related to nausea or caloric deficit
- Mood typically stabilizes as nausea resolves and the body adjusts
When to contact your provider:
- Significant mood changes in either direction that persist beyond the first few weeks
- Persistent low mood, anhedonia (loss of pleasure), or hopelessness
- Increased anxiety that interferes with daily function
- Any thoughts of self-harm or suicide
Your provider wants to know about mood changes because they affect your safety and treatment plan. If you develop significant depression symptoms on GLP-1, that may warrant a dose adjustment, medication change, or additional mental health support. If you have suicidal thoughts, get help right away: call or text 988 (Suicide and Crisis Lifeline), and contact your provider and a mental health professional.
When to Contact Your Provider About Mood Changes
Mild mood shifts in the first 1-2 weeks are common. Significant or persistent mood changes warrant contact with your provider. Reach out if you experience:
- Significant mood changes in either direction that persist beyond the first few weeks
- Persistent low mood or hopelessness lasting more than a few days
- Loss of interest or pleasure in activities you normally enjoy
- New or worsening anxiety that interferes with sleep or daily function
- Increased irritability or emotional sensitivity
Seek emergency care immediately if you experience:
- Thoughts of harming yourself
- Suicidal thoughts or urges
- Severe, uncontrollable emotional distress
Call or text 988 (Suicide and Crisis Lifeline), available 24 hours a day, or go to your nearest emergency room. If you are in immediate danger, call 911.
The bigger picture: weight loss and mental health
Weight loss and mood are linked in complex ways. Losing weight usually improves mood and self-image, but it is not guaranteed, and it is not linear. Some people feel better quickly. Others feel worse before they feel better, as they process changes in body image or face emotions they were previously numbing with food.
Your relationship with food, your body, and your identity matters. GLP-1 medications reduce the biological drive to eat, but they do not change your thoughts, beliefs, or emotional patterns around food and body. Nutrition guidance, physical activity, and mental health support address this broader context. Some programs include coaching or nutrition support and some do not, so check what a program actually offers. Mental health support, whether through a therapist, counselor, or other mental health professional, matters.
If you have a history of depression or disordered eating, tell your provider. There is no shame in this. Your provider needs the full picture to support you safely.
How the process should work
Starting a GLP-1 medication when you have depression or anxiety is possible, but it requires transparency and partnership with your provider. Programs differ, but a careful process usually looks like this:
Health history: You share your full health history, including mental health history, medications, and any past suicidal thoughts or attempts. Be wary of any program that does not ask about mental health at all.
Provider review: At most telehealth programs, a licensed provider (a physician, nurse practitioner, or physician assistant) reviews your information and decides whether a prescription is appropriate for you.
A chance to ask questions: Many programs offer a phone, video, or message-based visit to discuss your goals and history. Ask how mood changes are handled during treatment.
Prescription (if appropriate): If the provider decides a GLP-1 medication is appropriate, they write a prescription. Ask whether it is an FDA-approved brand-name medication or a compounded product. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality.
Follow-up: Ask how often the provider checks in, how you reach them between visits, and what happens if your mood changes. If you already see a therapist or psychiatrist, let both know about each other.
Programs also differ in cost and in what is included. Prices vary by program and dose, so compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
If you have a history of depression and you are considering GLP-1 treatment, this is a conversation worth having with your provider. The current evidence has not shown that GLP-1 medications worsen depression or cause suicidal thoughts, and some studies suggest a possible benefit, but that is not guaranteed for any one person. Your individual circumstances and mental health stability matter most.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedTransformation Health does not accept payment from providers. How we make money.
Citations
[1] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
[2] Wadden TA, Brown GK, Egebjerg C, et al. “Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.” JAMA Internal Medicine. 2024;184(11):1290-1300. https://pubmed.ncbi.nlm.nih.gov/39226070/
[3] Wang W, Volkow ND, Berger NA, et al. “Association of semaglutide with risk of suicidal ideation in a real-world cohort.” Nature Medicine. 2024;30(1):168-176. https://pubmed.ncbi.nlm.nih.gov/38182782/
[4] FDA. “Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity.” Drug Safety Communication. January 11, 2024. https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
[5] FDA. “FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.” Drug Safety Communication. January 13, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
[6] FDA. Prescribing information for Wegovy (semaglutide) injection and tablets. Revised 06/2026 (Recent Major Changes lists Suicidal Behavior and Ideation (5.10) as removed 01/2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[7] FDA. Prescribing information for Zepbound (tirzepatide). Revised 08/2026 (Recent Major Changes lists Suicidal Behavior and Ideation as removed). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[8] Taipale H, Taylor M, Lahteenvuo M, et al. “Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.” The Lancet Psychiatry. 2026;13(4):327-335. https://pubmed.ncbi.nlm.nih.gov/41862258/
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, and never start, stop, or change a medication without guidance from your prescriber. If you are having thoughts of suicide or self-harm, call or text 988 (Suicide and Crisis Lifeline) or go to the nearest emergency room. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication. GLP-1 medications are not FDA-approved to treat depression or anxiety. A licensed provider decides whether a prescription is appropriate. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review them for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.